A GlobalData report has revealed that the major markets of the US, the UK, France, Germany, Italy, Spain, Japan and China will lead the growth in renal cell carcinoma (Rcc) from $2.1bn in 2013 to $3.6bn by 2023.
The report, titled "’Renal Cell Carcinoma-Global Drug Forecast and Market Analysis to 2023‘, says that this growth, equivalent to a CAGR of 5.6%, will be assisted by the increase in the drug intake and a significant rise in the incidence of RCC.
It further mentions that Bristol-Myers Squibb’s immune checkpoint inhibitor drug Opdivo, already marketed in the US, will lead the competition, which includes Roche‘s Avastin and Pfizer‘s Inlyta, in the RCC market. Opdivo will be a ‘blockbuster’ RCC drug by 2023, according to the report.
The results of a phase 3 study to evaluate the efficacy of opdivo in combination with a new immune therapy Yervoy show that the overall survival in untreated patients with advanced melanoma increases in the combination therapies compared to monotherapies making Opdivo commercially successful, says GlobalData’s analyst, Maxime Bourgognon, PharmD.
GlobalData analyst James Beggs, Ph.D, predicts that efficacy coupled with safe profile, price, administration, familiarity with physicians and marketing experience in RCC gives the three combinations, Opdivo, Avastin and Inlyta, an edge over their competitors, enabling them to command a significant market share.
